45 results about "Immune inflammation" patented technology

Provided in the present invention are an anti-TLR7 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition thereof. The antibody or the antigen-binding fragment thereof can specifically bind to a human or simian TLR7 antigen and does not bind to murine TLR7, exhibits significant TLR7 antigen-binding activity, and can effectively inhibit various inflammatory cytokines produced upon TLR7 activation. The anti-TLR7 antibody or the antigen-binding fragment thereof can be used, either as a monotherapy or in combination with other drugs, for treating and / or preventing diseases pathologically associated with the TLR7 target, including immune inflammation-related diseases, allergic diseases, infectious diseases, cancers, etc.

The invention provides an anti-TLR7 antibody or an antigen binding fragment and a pharmaceutical composition thereof, the antibody or the antigen binding fragment thereof can be specifically bound with a human or monkey TLR7 antigen and is not bound with mouse TLR7, has remarkable TLR7 antigen binding activity, and can effectively inhibit various inflammatory cytokines generated by TLR7 activation. The anti-TLR7 antibody or the antigen binding fragment thereof can be used as a single agent or a drug combination and can be used for treating and / or preventing diseases related to TLR7 target pathology, including immune inflammation related diseases, allergic diseases, infectious diseases or cancers and the like.

The present invention provides novel drug-linker conjugates and antibody-drug conjugates of imidazo quinoline amine derivatives, which have agonistic activity against Toll-like receptors (TLRs), in particular TLR7 and / or TLR8, also provided are pharmaceutical compositions and methods of treatment against certain diseases or conditions mediated by or associated with TLR7 and / or TLR8 (e.g., graft rejection, autoimmunity, inflammation, allergy, asthma, infection, sepsis, cancer, and immunodeficiency).

The invention provides a skin repairing composition for relieving red, itching and dry symptoms of sensitive skin and application, and belongs to the technical field of cosmetics. The composition comprises an effective amount of an extract of at least two algae selected from the group consisting of Phaeodactylum tricornutum, Spirulina, Chlorella and Micrococcus, and optionally comprises other skin repair ingredients cooperating therewith. The skin repair composition for relieving red, itching and dry symptoms of sensitive skin simultaneously and synergistically intervenes four major causes of sensitive skin formation, namely barrier damage, hyperneurosis, immune inflammation and micro-ecological imbalance, breaks vicious circle and establishes a repair closed loop by utilizing the multiple effects of specific algae active ingredients, and has the effects of relieving the symptoms of red, itching and dry symptoms of sensitive skin and relieving the symptoms of red, itching and dry symptoms of sensitive skin. Therefore, the problems of red skin, itching skin, dry skin and the like are radically relieved.

This invention discloses a method, system, and medium for dynamic prediction of pregnancy complications in SLE patients, belonging to the field of medical information technology. It aims to solve the technical problems of existing risk assessment methods, such as the inability to effectively integrate multi-dimensional time-series data and the lack of causal mechanism analysis of the dynamic evolution of risk, resulting in biased, delayed, and clinically inoperable prediction results. The method includes the following steps: S1: Acquiring multimodal health data of the target patient during pregnancy as a time series; S2: Based on the multimodal health data, constructing and updating a dynamic patient profile reflecting the patient's psychosocial state, immune inflammatory activity, and target organ function; S3: Inputting the dynamic patient profile into a trained risk prediction model. This invention, by constructing a dynamic patient profile and employing a time-series deep learning model for risk prediction, achieves a comprehensive, dynamic, and mechanistically transparent risk assessment of pregnancy complications in SLE patients.

The application belongs to the technical field of biological medicine, and particularly relates to a binding molecule targeting CCL5 and application of the binding molecule in combination with drugs in treatment of Th2-type inflammation related diseases. The application discloses use of a binding molecule targeting CCL5 or a pharmaceutical composition comprising the binding molecule in preparation of a product having one or more of the following functions: 1) prevention and / or treatment of Th2-type inflammation related diseases; 2) reduction of skin lesion tissue thickness; 3) reduction of clinical score of atopic dermatitis; 4) reduction of scratching behavior; 5) reduction of tissue damage; 6) alleviation of inflammatory reaction and inhibition of expression of inflammatory factors; and 7) reduction of inflammatory cell infiltration. The binding molecule targeting CCL5 or the pharmaceutical composition comprising the binding molecule has important value in prevention and treatment of immune inflammatory diseases such as atopic dermatitis, allergic rhinitis, asthma, food allergy or drug allergy.

The invention discloses a construction method of a sensitive skin animal model, and belongs to the technical field of animal model construction. According to the method disclosed by the invention, the sensitive skin animal model is constructed by smearing the lauryl sodium sulfate on the back skin of the mouse after hair removal in combination with veratrine or capsaicin, so that physiological indexes of human sensitive skin can be simulated; key pathological processes of human sensitive skin can be simulated by detecting key pathological indexes such as skin barrier damage, nerve and blood vessel high reactivity, immune inflammation and the like, natural pathophysiological processes of human sensitive skin can be simulated, and pathogenesis of sensitive skin is basically covered; barrier destruction of mouse skin, high reactivity of nerve and blood vessels and inflammatory response are induced, and clinical practice is met. In addition, the method is good in repeatability, high in safety and easy and convenient to operate, sensitive skin medicine screening and personalized treatment scheme development can be promoted, the research and development period of sensitive skin related treatment schemes is shortened, and the application prospect is good.

The invention discloses a model for early prediction of acute kidney injury risk after geriatric sepsis patients are transferred into ICU based on clinical variables and immune inflammation indexes, 627 geriatric sepsis patients are included in the research, and the clinical variables and immune inflammation indexes of the geriatric sepsis patients in the ICU within 24 hours are collected; clinical variables of the first 6 ranked and immune inflammation indexes of the first 4 ranked related to acute kidney injury are screened out, prediction models are constructed through four machine learning algorithms respectively, the model prediction performance of the XGBoost algorithm is the best, the model prediction performance of the logistic regression algorithm is the second, and the model prediction performance of the XGBoost algorithm is the best. And a visual column diagram is made according to a logistic regression algorithm, and an early prediction model with good accuracy is established.

The present disclosure provides antibodies that bind to CD40, and methods of using them to modulate immunity in a patient in need thereof and to treat autoimmune disorders or immunoinflammatory disorders.

The application discloses a kind of S3B polypeptide with SHP2 as action target point and its application in treating tumor and inflammation.The amino acid sequence of the polypeptide is RLLREEEYVAPPRGPLPTLQVVPL, the amino acid sequence of transmembrane peptide included in the polypeptide is TAT:YGRKKRRQRRR, the polypeptide can enter cell after being wrapped by liposome, inhibits QPCTL enzyme activity, promotes the degradation of SHP2 protein, thereby playing the role of inhibiting tumor cell proliferation, migration and growth, etc., to achieve the purpose of treating tumor and other diseases.The application provides a certain reference for treating SHP2 related tumor or immune inflammatory disease and developing new SHP2 degradation drug.

This invention discloses the application of C5aR1 antagonists and / or IL-1β inhibitors in the preparation of drugs for treating congenital heart disease with pulmonary hypovascularity. This invention breaks through the limitations of traditional single surgical procedures, providing for the first time a targeted, effective, and safe drug treatment strategy from a novel perspective of immune inflammation regulation. This strategy not only effectively promotes lung development and improves patients' physiological indicators, but also safeguards high-risk surgeries, ultimately comprehensively improving the prognosis and quality of life for patients with congenital heart disease with pulmonary hypovascularity.

The present application relates to an anti-inflammatory peptide comprising one or more selected from the group consisting of amino acid sequences of SEQ ID NO. 1 to SEQ ID NO. 63 and modified amino acid sequences thereof, an anti-inflammatory composition comprising the same, and a pharmaceutical composition for preventing or treating an inflammatory disease. The anti-inflammatory peptide according to an embodiment of the present application has no cytotoxicity and has an effect of inhibiting the expression or activity of MAVS activation, immune / inflammatory activation reaction mechanisms, inflammatory cytokines, and inflammasomes, and the like, and the above peptide can be applied to an anti-inflammatory composition or a composition for treating an inflammatory disease.

The invention discloses jute homogeneous polysaccharide with an immune activation effect as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention aims to solve the technical problems of improving immune organ atrophy, caused by cyclophosphamide, of an immunosuppression model mouse, recovering morphological characteristics and blood cell quantity of the spleen and promoting generation of immune and inflammatory cytokines, so that the immune function of the mouse is recovered, and the effect of immune activation is achieved. The technical scheme is characterized in that the jute homogeneous polysaccharide is formed by connecting 3-4 parts by mole of rhamnose, 0.5-2 parts by mole of arabinose, 1-3 parts by mole of galactose and 1-2 parts by mole of galacturonic acid through glucosidic bonds.

This invention discloses a traditional Chinese medicine shampoo for androgenetic alopecia caused by liver and kidney deficiency, its preparation method, and its application. Belonging to the field of traditional Chinese medicine technology, the shampoo uses processed Polygonum multiflorum, wine-processed Ligustrum lucidum, Eclipta prostrata, ginseng, Angelica sinensis, safflower, Salvia miltiorrhiza, Platycladus orientalis leaves, mulberry leaves, honey-processed mulberry bark, Sophora flavescens, Cnidium monnieri, Paeonia suffruticosa, Cercis chinensis bark, ginger, Sapindus mukorossi, Gleditsia sinensis, and Clematis chinensis as raw materials, prepared through water extraction and concentration. This invention achieves both symptomatic and root-cause treatment, addressing both the underlying cause and symptoms. It intervenes in androgenetic alopecia through the HIF-1 / VEGE and IL-17 pathways, promoting angiogenesis and improving microcirculation in the scalp, inhibiting follicular immune inflammation, and creating a favorable environment for hair follicle growth. Compared with existing technologies, this invention has irreplaceable advantages in improving local symptoms such as oily scalp, itching, and dandruff.

The application relates to a rapamycin-G4H nanocapsule, a preparation method and application thereof. The preparation method of the rapamycin-G4H nanocapsule comprises the following steps: S1. preparing a rapamycin micelle by adopting a film hydration method; S2. modifying a dibenzocyclooctyne amplification primer on the surface of the rapamycin micelle through a click chemistry reaction to obtain a rapamycin micelle modified with the amplification primer; S3. taking a linear DNA molecule as a template, and synthesizing a circular amplification template through an intramolecular cyclization reaction; and S4. incubating the circular amplification template, the rapamycin micelle modified with the amplification primer, a thermophilic DNA polymerase, a pyrophosphatase, dNTP and Co-G4-haem DNAzyme under the condition of a thermophilic DNA polymerase reaction buffer. The rapamycin-G4H nanocapsule can play an efficient antioxidant stress and immune inflammatory regulation function, can improve the intraocular microenvironment of a glaucoma patient, and can inhibit the continuous apoptosis of retinal ganglion cells.

The invention discloses a Karenia mikimotoi red tide biotoxicity and risk assessment method, and belongs to the field of marine environment monitoring and ecological risk assessment. The method comprises the steps of karenia mikimotoi culture, marine model fish model establishment, karenia mikimotoi exposure, multi-system toxicity index detection and data analysis. By integrating five toxic pathways (hemolysis injury, detoxification metabolism, oxidative stress, immune inflammation and reproductive function), systematic evaluation from a micromechanism (gene / cell) to a macroscopic effect (tissue / individual) is realized, and a toxic action mechanism is comprehensively revealed. By means of LDH, blood sugar, ROS and other sub-lethal indexes, early warning is achieved before irreversible injury occurs, and more abundant response time is provided for red tide disaster prevention. Traditional phenomenon observation is broken through, multi-system dysfunction caused by energy depletion, immune attack and other new mechanisms of Karenia mikimotoi is revealed through a key gene expression mode, and a new target is provided for toxicity prevention and control.

The invention relates to an application of L-tartaric acid or a soluble salt thereof in inflammation inhibition. The L-tartaric acid or the soluble salt thereof is used for inhibiting inflammation. The invention provides and verifies that L-tartaric acid can significantly inhibit expression and secretion of IL-6, IL-1beta and TNF-alpha in RAW264.7 cells induced by LPS, has clear anti-inflammatory activity, fills up the research blank of L-tartaric acid in the field of immune inflammation regulation and control, and provides technical support for extended application of L-tartaric acid in the fields of anti-inflammatory drugs, functional foods and the like.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a kidney-tonifying and dampness-removing traditional Chinese medicine composition and a preparation method and application thereof. The traditional Chinese medicine composition capable of tonifying kidney and promoting diuresis is prepared from the following raw materials in parts by weight: 60 to 120 parts of radix astragali seu hedysari, 60 to 120 parts of fructus ligustri lucidi, 120 to 240 parts of herba taraxaci, 120 to 240 parts of rhizoma imperatae, 40 to 80 parts of semen persicae, 60 to 120 parts of radix paeoniae rubra, 120 to 240 parts of herba leonuri, 120 to 240 parts of folium pyrrosiae, 20 to 40 parts of flos carthami and 80 to 160 parts of radix ilicis pubescentis. The traditional Chinese medicine composition for tonifying kidney and promoting diuresis provided by the invention regulates immune inflammatory response through multiple mechanisms and multiple targets, improves kidney pathology, and potentially intervenes the action mechanism of intestinal-renal axis disorder.

This invention discloses a method for restoring TREM2 in the preparation of diabetic nephropathy using luteolin. + This invention relates to the application and research methods of macrophage functional drugs, and pertains to the field of biomedical technology. Through the technical solution of this invention, luteolin is used for the intervention of diabetic nephropathy, achieving the effect of regulating TREM2. + Targeted regulation of the key pathological link of macrophage dysfunction; by increasing TREM2 + The number and functional status of macrophages are improved, enhancing their ability to eliminate apoptotic cells, reducing the level of renal tissue cell apoptosis and immune inflammatory damage; thereby alleviating the progression of kidney damage in diabetic nephropathy.

The present invention provides a TL1A binding molecule and a use thereof. Specifically, the present invention provides an anti-TL1A single-domain antibody or an antigen-binding fragment thereof, which can bind to human and cynomolgus monkey TL1A and block the TL1A / DR3 pathway, but does not affect the binding of TL1A to a natural blocker DcR3 of the TL1A / DR3 pathway. The anti-TL1A single-domain antibody or the antigen-binding fragment thereof in the present invention has high stability, and can be prepared into formulations of various dosage forms. Therefore, the anti-TL1A single-domain antibody or the antigen-binding fragment thereof in the present invention can be used as a novel therapeutic agent for the treatment of immune / inflammation-related diseases.

The invention discloses a gastric cancer tumor immune microenvironment typing method and system and application in prognosis prediction. The method comprises the following steps: carrying out multiple immunohistochemical staining on a patient tissue sample and obtaining a full-view image, segmenting a tumor region and a matrix region in the image, identifying CD3 + T cells and counting, and calculating the CD3 + T cell density of the two regions and the CD3 + T cell ratio of the matrix region. Typing according to a threshold value type 3: the tumor region with CD3 + T cell density greater than or equal to 1000 cells / mm < 2 > is an immune inflammation type; the tumor region CD3 + T cell density is lt; 1000 cells / mm < 2 > and the ratio of CD3 + T cells in a matrix region is 1t; 0.18 is an immune desert type; the tumor region CD3 + T cell density is lt; and if the ratio of CD3 + T cells in a matrix region is greater than or equal to 0.18, the cells are in an immunoexclusion type. The method can provide risk stratification information (data prompt) related to OS / PFS in vitro.

The present application relates to a kind of mesenchymal stem cells of overexpressing HDAC9 and its preparation method and application, belong to stem cell therapy technical field.The present application overexpressing HDAC9 mesenchymal stem cell includes the nucleotide sequence as shown in SEQ ID NO:1 or SEQ ID NO:2 and dCas9-target plasmid.The present application constructs MSCs of HDAC9 gene modification for the first time, improves its inhibition effect to immune inflammation, so as to promote its treatment effect in immune inflammation.

The invention discloses a method, a device, equipment and a medium for predicting the reaching of pCR of neoadjuvant chemotherapy of triple negative breast cancer, and relates to the technical field of medical data processing, and the method comprises the following steps: obtaining clinical pathological characteristics of a to-be-detected object and peripheral blood counting data before neoadjuvant chemotherapy; the peripheral blood count data comprises neutrophil count, lymphocyte count, platelet count and mononuclear cell count; the clinical pathological characteristics comprise a T staging characteristic, an N staging characteristic and a Ki-67 characteristic; determining a target biomarker related to pathologic complete remission pCR prediction based on the peripheral blood count data, and calculating an immune inflammation score according to the target biomarker; the clinical pathological features and the immune inflammation scores are processed through a trained XGB model, and a pCR prediction result of the to-be-detected object is obtained; and the XGB model is used for capturing a nonlinear relationship and an interaction effect among the data. According to the invention, the problem of poor detection timeliness can be avoided, and the pCR prediction accuracy is improved at the same time.

The invention relates to aromatic hydrocarbon receptor modulator compounds represented by the following formula I, respective optical isomers, deuterated compounds, prodrugs or pharmaceutically acceptable salts thereof, and a preparation method and application of the aromatic hydrocarbon receptor modulator compounds and the optical isomers, the deuterated compounds, the prodrugs or the pharmaceutically acceptable salts thereof. The compound can be used as an aromatic hydrocarbon receptor regulator for regulating the activity of an aromatic hydrocarbon receptor in a body, and has very important significance on treatment of related diseases such as immunity, inflammation, infection, skin diseases, osteoporosis, cancers and neurodegenerative diseases.

The present invention relates to uses of regulatory T cells manipulated to overexpress CX3CR1. The regulatory T cells induced to overexpress CX3CR1 according to the present invention reduce microglial activation in an LPS-induced neuroinflammation animal model and suppress immune inflammatory responses of activated microglia by inhibiting the expression of pro-inflammatory markers and cytokines in the cortical and hippocampal regions of the brain, and thus can be used for reducing microglial activation or for treating neuroinflammatory diseases or neurodegenerative diseases caused by hyperactivation of microglia in the brain.

The application discloses a preparation method and application of a metal organic framework composite coating of active molecules loaded on a zinc alloy surface, and belongs to the technical field of biomedically degradable metal materials. The preparation method of the organic metal framework composite coating comprises the following steps: S1, preparing a ZnO nanostructure transition layer; S2, in-situ generating a metal organic framework coating induced by 2,5-dihydroxyterephthalic acid; and S3, preparing a metal organic framework composite coating loaded with deferoxamine. The application can effectively slow down the degradation rate of a zinc alloy substrate containing Mg, Ca and Sr, and makes the zinc alloy substrate containing Mg, Ca and Sr free of local corrosion, so that no toxicity is caused to cells and tissues around an implantation site. Slow release of the loaded deferoxamine can significantly accelerate blood supply reconstruction at a fracture / bone defect site, and can balance osteogenesis and osteoclastogenesis. The application solves the problems of uncontrollable degradation and lack of regulation on local immune inflammation and osteogenesis-osteoclastogenesis balance.

The invention discloses an ergothioneine-non-denatured II-type collagen peptide pet anti-aging rehabilitation composition with anti-oxidation, joint repair and intestinal regulation functions and application thereof, and belongs to the technical field of pet health and nutrition. The composition consists of ergothioneine, non-denatured type II collagen peptide, prebiotics, metabiotics, vitamin E, vitamin C and the balance of a carrier acceptable for pets. According to the invention, the ergothioneine with high bioavailability, the non-denatured II type collagen peptide and the metagen are combined and applied to the anti-aging field of pets for the first time, and a triple pathway synergistic anti-aging model is innovatively constructed, namely, the effect is achieved by regulating intestinal flora, activating an endogenous antioxidant system and regulating immune inflammation balance. The composition is clear in action mechanism, remarkable in effect and high in safety, and a scientific and effective new nutrition intervention scheme is provided for delaying the pet aging process and promoting postoperative rehabilitation.

The invention discloses application of N-arachinoylglycine in preparation of a medicine for treating inflammation-related diseases and belongs to the technical field of medicines, the N-arachinoylglycine is NAGLY, belongs to an acyl glycine compound and can participate in various signal transduction pathways including activation of a G protein coupled receptor, the receptor is related to an inflammation pathway, and the N-arachinoylglycine can be used for preparing a medicine for treating inflammation-related diseases. The invention further discloses application of NAGLY in preparation of drugs for treating ulcerative inflammation related diseases, and experiments prove that after an immune inflammatory reaction inducer lipopolysaccharide LPS is used for inducing an inflammatory reaction in mouse mononuclear macrophages RAW264.7, the N-arachinoylglycine can effectively inhibit expression of inflammatory factors, so that the NAGLY can be used for preparing drugs for treating ulcerative inflammation related diseases, and can be used for preparing drugs for treating ulcerative inflammation related diseases. And a new direction is provided for research and development of medicines for treating diseases related to ulcerative inflammation.

This invention discloses a dynamic monitoring and analysis system for immune inflammation in patients with glomerular diseases, applicable to the field of medical testing and data analysis. The system includes a data acquisition module, a multi-omics detection module, a dynamic data analysis module, a visualization and reporting module, and an early warning module. The multi-omics detection module integrates the joint detection of immune inflammation-related proteins (such as CCL11 and CXCL9), metabolic markers (such as N-acetyl-L-leucine), and oxidative stress markers (such as RAC2). The dynamic data analysis module is built based on the XGBoost algorithm and calculates a "dynamic immune score" to quantitatively assess disease activity and predict trends. This invention overcomes the shortcomings of traditional single-marker methods, such as poor specificity and inability to dynamically monitor, achieving non-invasive, multi-dimensional, and real-time monitoring of the immune inflammatory status of glomerular diseases, providing decision support for precise clinical diagnosis and treatment.

The invention relates to the technical field of functional compositions, in particular to a multi-target-point synergistic composition with the relieving and flash repairing efficacy, a preparation method and application thereof.The multi-target-point synergistic composition with the relieving and flash repairing efficacy is prepared from, by mass, 3%-10% of an RS-configuration bose solution, 1%-1.2% of ectoine, 0.08%-0.1% of ceramide NP, 1%-1.5% of a crocus sativus extract and the balance water. By optimizing the matching of the components, the provided composition can simultaneously act on skin barrier repair, nerve-immune inflammation inhibition, microcirculation improvement and skin structure strengthening, the limitation of an existing single-channel repair product is overcome, and the repair effect is good. And the double repairing goals of rapid relieving and long-term toughness are achieved.